restor3d has launched MyFit by restor3d Digital Suite, a new platform intended to provide patients with improved visibility and engagement throughout their orthopaedic care process.
The suite connects patients, surgeons, and clinical outcomes through digital tools designed to extend personalisation beyond implant design into the patient experience.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It facilitates communication between patients and their care teams via automated messages and an interactive portal.
Patients will be able to receive updates as their custom implant is created, follow its progress, and, in certain procedures, view a 3D model of their implant design in advance of surgery.
These features are intended to give patients more information about their treatment and enable ongoing engagement with their care.
restor3d CEO Kurt Jacobus said: “Personalisation has always been at the centre of what we do at restor3d, and MyFit by restor3d allows us to bring that same philosophy directly to the patient experience.
“Patients undergoing joint replacement are increasingly engaged in their care and want to better understand the technology and treatment designed specifically for them.
“MyFit by restor3d gives patients a unique connection to their personalised implant while allowing us to continue learning from their outcomes over time.”
The platform offers a variety of experiences tailored to restor3d’s different orthopaedic product areas.
Hip and knee patients receive automated SMS messages at key stages, from enrolment and design to manufacturing and surgery preparation through MyFit Connect by restor3d.
Shoulder, foot and ankle patients can access a patient portal for status updates and an interactive 3D model of their implant.
Portal access requires only identifying information, without the need for a password.
These features aim to keep patients informed without increasing administrative workloads for clinicians.
Patients can also enrol in the restor3d Patient-Specific Registry, which collects patient-reported outcomes from baseline up to five years post-surgery.
The registry targets around 2,250 participants across knee, hip, shoulder, and foot and ankle procedures, seeking to gather electronic outcome data while reducing requirements for participating practices.
The company described this launch as part of its wider initiative to build a connected process encompassing planning, implant design, manufacturing, surgery, engagement, and outcome tracking.
In April 2025, the US Food and Drug Administration granted 510(k) clearance for restor3d’s cementless iTotal Identity CR 3DP Porous Total Knee Replacement System.
